Abstract
Objective:
Internal superior laryngeal nerve (iSLN) injections demonstrate short term improvements in patients with laryngeal neurosensory disturbances (ie, chronic refractory cough and globus pharyngeus) that can require multiple injections. A more targeted iSLN injection approach could provide greater effectiveness. This study prospectively evaluated whether transnasal endoscopic iSLN injections that target the internal iSLN as it transverses the piriform sinuses was effective at treating laryngeal neurosensory disturbances.
Methods:
This was a prospective cohort analysis performed at a single tertiary care center. Patients with laryngeal neurosensory disturbances underwent transnasal endoscopic iSLN injections bilaterally using triamcinolone-40 mg/mL. Demographics, clinical history, and exam findings were recorded, along with post-injection complications. The primary outcomes were the Leister Cough Questionnaire (LCQ), Reflux Symptom Index (RSI), and the Voice Handicap Index-10 (VHI-10) collected at pre-injection, 3-weeks post-injection, and 2-months post-injection that were examined with linear mixed modeling.
Results:
Eighteen patients with laryngeal sensory disturbances (11 with chronic cough and 7 with globus sensation) underwent the procedure. There were significant improvements in LCQ scores (all greater than 1.3 points) and RSI scores (all greater than 7-point improvement) at both 3-week and 2-month timepoints (P < .05). When stratified into globus sensation patients alone, there was significant improvements in LCQ at 3 weeks (3.92 points, P = .02) as well as across both 3-week and 2-month timepoints (14 points, P < .001; 7.4 points, P = .04). There were no aspiration events or major complications.
Conclusions:
Targeted transnasal endoscopic iSLN injections of the piriform sinus mucosa appears to be a safe and effective way of treating laryngeal neurosensory disturbances. The technique provides a visual target for injection of the iSLN which may allow for exploration of alternative neuromodulating medicines for use in this patient population.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
